Beam Therapeutics

Contributing Author

Recent Articles by Beam Therapeutics

May-29	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-14	Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress BEAM GlobeNewswire
May-13	Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference BEAM GlobeNewswire
May-12	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) BEAM GlobeNewswire
May-06	Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights BEAM GlobeNewswire